Scorpius Holdings
Innovative medical countermeasures accelerating drug development through a fully integrated biopharmaceutical ecosystem.
| USD | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | 281 % | (47 %) | (3 %) | (28 %) | 183 % | (18 %) | 320 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (297 %) | (592 %) | (759 %) | (1471 %) | (681 %) | - | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (272 %) | (657 %) | (884 %) | (1660 %) | (726 %) | - | - |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 280 % | 427 % | 439 % | 891 % | 392 % | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
NightHawk Biosciences, Inc. is a biopharmaceutical company focused on accelerating the development of innovative medical countermeasures. The company operates within the healthcare and biotechnology sectors, serving clients that include government agencies, healthcare providers, and pharmaceutical companies. NightHawk leverages a fully integrated ecosystem, which includes the discovery efforts of SkunkWorx Bio, Inc., the development and commercial expertise of Elusys Therapeutics, Inc., and the contract research and development biomanufacturing services of Scorpius Biological Services. This integrated approach allows NightHawk to streamline the drug development process, breaking through barriers that typically prolong the creation of new medical treatments.
NightHawk's business model revolves around research and development, contract manufacturing, and commercialization of medical countermeasures. The company generates revenue through government contracts, partnerships with pharmaceutical companies, and sales of its proprietary medical solutions. By focusing on innovative solutions and leveraging its comprehensive ecosystem, NightHawk aims to address unmet medical needs and improve public health outcomes.
Keywords: biopharmaceutical, medical countermeasures, drug development, integrated ecosystem, biotechnology, healthcare, government contracts, pharmaceutical partnerships, biomanufacturing, innovation.
Investments by Scorpius Holdings
Edit